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Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is a chronic, irreversible disease and a leading cause 
of worldwide morbidity and mortality. In Canada, COPD is the fourth leading cause of death. This systematic review 
was undertaken to update healthcare professionals and decision makers regarding the recent clinical, humanistic and 
economic burden evidence in Canada.
Methods: A systematic literature search was conducted in PubMed, EMBASE, and Cochrane databases to identify 
original research published January 2000 through December 2012 on the burden of COPD in Canada. Each search 
was conducted using controlled vocabulary and key words, with “COPD” as the main search concept and limited to 
Canadian studies, written in English and involving human subjects. Selected studies included randomized controlled 
trials, observational studies and systematic reviews/meta‑analyses that reported healthcare resource utilization, qual‑
ity of life and/or healthcare costs.
Results: Of the 972 articles identified through the literature searches, 70 studies were included in this review. These 
studies were determined to have an overall good quality based on the quality assessment. COPD patients were found 
to average 0–4 annual emergency department visits, 0.3–1.5 annual hospital visits, and 0.7–5 annual physician visits. 
Self‑care management was found to lessen the overall risk of emergency department (ED) visits, hospitalization 
and unscheduled physician visits. Additionally, integrated care decreased the mean number of hospitalizations and 
telephone support reduced the number of annual physician visits. Overall, 60–68 % of COPD patients were found 
to be inactive and 60–72 % reported activity restriction. Pain was found to negatively correlate with physical activ‑
ity while breathing difficulties resulted in an inability to leave home and reduced the ability to handle activities of 
daily living. Evidence indicated that treating COPD improved patients’ overall quality of life. The average total cost per 
patient ranged between CAN $2444–4391 from a patient perspective to CAN $3910–6693 from a societal perspective. 
Furthermore, evidence indicated that COPD exacerbations lead to higher costs.
Conclusions: The clinical, humanistic and economic burden of COPD in Canada is substantial. Use of self‑care man‑
agement programs, telephone support, and integrated care may reduce the overall burden to Canadian patients and 
society.
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Background
Chronic obstructive pulmonary disease (COPD) is a 
persistent, irreversible, progressive disease exacting a 
heavy toll on patients and caregivers and is a leading 
cause of morbidity and mortality worldwide [1–4]. Esti-
mates indicate that more than 10 % of the adult popula-
tion are affected by COPD, and one in four adults over 
the age of 35 will develop COPD in their lifetime [5, 
6]. In Canada, COPD is project to be the fourth lead-
ing cause of death behind heart disease, cancer and 
stroke and is expected to be the third leading cause of 
death by 2020 [3]. Exposure to environmental factors 
is thought to be the major underlying cause of COPD, 
with smoking being the most important risk factor [7–
9]. Comorbidities, such as cardiovascular disease, are 
very common and are thought to contribute to the vast 
majority of COPD deaths [10–12].
The unique features of the Canadian universal health-
care system provide different challenges for govern-
ment and health care providers alike in the delivery and 
implementation of health services. With the substantial 
burden and societal importance of COPD, it is important 
for Canadian healthcare professionals and decision mak-
ers to remain up to date with evidence of managing and 
treating COPD. A sizeable body of research on the bur-
den of COPD in Canada has been conducted in recent 
years; however, a systematic review of recent evidence is 
lacking. The overall purpose of this systematic review is 
to update the knowledge of the burden of COPD in Can-
ada by summarizing the most current, evidence-based 
information. The specific objective is to summarize the 
recent literature describing the clinical, humanistic and 
economic burden of COPD among Canadians.
Methods
Literature search
We conducted a search of the PubMed, EMBASE, and 
Cochrane databases to identify original research (obser-
vational and interventional studies, burden of illness 
studies, and cost of illness studies) published January 
2000 through December 2012 on the burden of COPD 
in Canada. Non-systematic review articles, letters, edi-
torials, commentaries, studies reporting summaries of 
meeting proceedings or conferences, abstracts or posters 
presented at scientific meetings, and studies examining 
the efficacy or effectiveness of specific pharmacother-
apy interventions were not included. Each search was 
conducted using controlled vocabulary and key words 
and was limited to articles published in English, stud-
ies conducted with Canadian data, and studies involving 
humans. Additional articles were identified and added 
to each review through a review of the bibliographies of 
included articles and if identified in the other literature 
search (i.e. article with economic data found in humanis-
tic literature search).
Study selection
Titles and abstracts of articles identified were carefully 
screened in the initial review for relevance to the topic 
by a single reviewer. Articles were selected for inclusion 
based on predefined acceptance criteria, which included 
relevant patient population (i.e., adults/children diag-
nosed with COPD), study design [randomized controlled 
trial (RCT), observational study, systematic review/meta-
analyses] and outcome measures (healthcare resource 
utilization, quality of life, healthcare costs). Complete 
articles were obtained for any article that categorized as 
‘included’ or ‘unsure’ after the title and abstract review. 
All ‘unsure’ articles were then reviewed to make a final 
determination of inclusion or exclusion. A second, inde-
pendent reviewer performed a check on a random sam-
ple of 20  % of the articles with discrepancies resolved 
through consensus. Articles identified as potentially rel-
evant were obtained in full text for further evaluation.
Data abstraction
Data abstraction forms were designed a priori. For arti-
cles that met predefined inclusion/exclusion criteria, 
key outcomes were abstracted and tabulated in sum-
mary tables. Key outcomes extracted included: emer-
gency department visits, hospitalization and office visits 
in the clinical burden literature; quality of life measures 
in the humanistic burden literature; patient and popula-
tion costs in the economic burden literature. In the eco-
nomic burden section, reported costs were inflated to 
2012 Canadian dollars using the Consumer Price Index 
from Statistics Canada (http://www.statcan.gc.ca). A 
second, independent reviewer performed a check on a 
random sample of the data abstracted from 20 % of the 
articles.
Quality assessment
Quality was assessed by using internationally recognized 
methodological checklists from the National Institute for 
Health and Care Excellence (NICE) Guidelines Manual 
for RCT [13], the strengthening the reporting of obser-
vational studies in epidemiology (STROBE) statement 
[14] for observational studies, and the PRISMA check-
list for systematic reviews and meta-analyses [15]. The 
NICE RCT checklist provides an assessment of potential 
bias in 4 categories: selection, performance, attrition and 
detection. The STROBE checklist contains 22 items that 
assess completeness of reporting in observational stud-
ies and the 27-item PRISMA checklist provides a similar 
assessment for systematic reviews and meta-analyses. 
The information collected in these checklists enabled a 
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decision to be made about the eligibility of the studies for 
inclusion in this project. A second, independent reviewer 
performed a quality review check on a random sample of 
20 % of the articles.
Results
Literature search
A total of 495 studies were identified by the clinical 
and economic burden literature searches with 58 stud-
ies being suitable for inclusion (Fig.  1). The 58 studies 
included: 3 systematic review/meta-analyses, 5 RCTs, 
and 27 cohort, 18 cross-sectional, and 5 case–control 
studies. A total of 477 studies were identified by the 
humanistic burden literature searches of which 12 studies 
were ultimately included (Fig. 2). The study designs of the 
12 included articles were 6 RCTs, 4 cross-sectional and 2 
case–control studies.
Quality assessment
The clinical and economic burden literature included 
3 systematic review/meta-analyses which met most of 
the PRISMA checklist criteria [16–18]. The criteria that 
were not met included: no description of methods for 
combining studies (100  %), not addressing risk of bias 
across studies (67  %) or individual studies (33  %) and 
not describing study limitations (67  %). Of the 5 RCTs 
appraised using the NICE RCT methodology checklist, 
most were rated as having a low risk of bias; however, 
a high risk of attrition bias was noted for three studies 
[19–21]. Lastly, the 50 remaining studies were assessed 
using the STROBE checklist. Many of the cohort studies 
did not indicate the study design (36 %), lacked reporting 
sensitivity or sub-group analyses (71 %), and missing or 
follow-up data was infrequently addressed (68 and 39 % 
respectively). The methodological limitations identified 
Fig. 1 Clinical/economic burden literature search results
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for the cross-sectional and case–control studies were 
very similar.
The humanistic burden literature included a total of 
6 RCTs which were appraised by the NICE RCT meth-
odology, all of which had an overall low risk of bias. The 
remaining 6 studies met most of the STROBE criteria; 
however, only 2 of the 6 studies adequately described 
the study setting [22, 23], 2 studies discussed efforts to 
address sources of bias [22, 24], and there was an overall 
lack of reporting on how missing data was addressed as 
well as sub-group and sensitivity analysis [23–27].
Clinical burden evidence results
Overview
Of the 57 articles with clinical burden data (Tables  1, 2 
and 3), the primary data source for 60  % of the studies 
(retrospective cohort and cross-sectional designs) was 
the provincial healthcare databases containing hospital 
records and pharmaceutical claims. The time frame of 
the included studies varied based on the study design. 
In general, the prospective designed studies included 
a much shorter time frame than systematic reviews or 
retrospective database analyses which often spanned 
decades.
Emergency department (ED) visits
Emergency department visits were reported as an out-
come in 23 out of the 58 studies (Table 1). A number of 
studies reported the mean number of emergency depart-
ment visits which ranged from 0.1 to 2.20 per year [1, 
17, 28–39]. Eleven studies reported that 7.2–63.2  % of 
patients with COPD visited the emergency department 
[1, 17, 21, 28, 30, 35, 40–44]. Johnston [32] reported the 
mean annual number of ED visits by disease severity. The 
instrument used to assess disease severity was devel-
oped by the global initiative for chronic obstructive lung 
Fig. 2 Humanistic literature search results
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disease (GOLD) and categorizes patients from mild to 
very severe in 4 levels (GOLD 1–4 stratum). The mean 
number of annual ED visits ranged from 1.4 (GOLD stra-
tum 1 and 2) to 1.8 (GOLD stratum 3 and 4) in COPD 
patients with an exacerbation [32].
Three studies reported how different pre/post interven-
tions affected ED visits in COPD patients. Overall ED 
visits were less in COPD patients with self-management 
education or self-care management programs; however, 
integrated care appeared to provide no benefit on the 
annual mean number of ED visits [28, 29, 44].
Hospitalization
Hospitalization was reported as an outcome in 38 of the 
58 studies (Table  2). The rates were reported as either 
pre- or post- index hospitalizations. The mean num-
ber of annual hospital visits per COPD patient per year 
ranged from: 0–1.5 pre-index to 0–5.19 post-index [1, 
28, 29, 32, 34, 41, 43, 45–48]. Three studies reported 
the rates of hospitalization according to disease sever-
ity and/or COPD exacerbations and found higher rates 
of hospitalization in more severe patients (GOLD stra-
tum 3 or 4) and those with more severe exacerbations 
[3, 32, 43]. Hospital readmission rates varied between 
three studies with Sin [49] reporting a rate of 25  % for 
COPD patients ≥65 years of age, Chen [50] reporting a 
rate of 49.1 % in patients ≥40 years of age, and Wong [47] 
reporting 3.3 mean annual number of hospital readmis-
sions in patients with a diagnosis of AECOPD.
The relationship of COPD hospitalization rates to 
patient demographic characteristics was examined in 
three studies. A higher rate of hospitalization was found 
in male COPD patients [126.1/1000 patient years (PY)] 
than females (74.3/1000 PY) and in those >65 years of age 
(5.19 visits/patient annually) versus those 45–64  years 
of age (3.45 visits/patient annually) [46, 51]. One study 
found that COPD patients’ body mass index (BMI) status 
had no effect on hospitalization rates [45].
Lastly, three studies examined the effects of different 
interventions on hospitalization rates in COPD patients. 
Moullec [28] found that integrated care (a combination 
of self-management education and case management) 
resulted in a decreased mean number of hospitalizations 
compared to usual care. Lebrecque [29] and Sedeno [21] 
found that self-management interventions also reduced 
hospitalizations compared to usual care.
Physician visits
A total of 24 studies reported the rate of physician vis-
its for COPD (Table 3). The annual rate of physician vis-
its post-index for COPD patients ranged between 1.57 
and 28 visits annually [41, 46, 52]. Two studies found 
that elderly COPD patients (>65  years) had high rates 
of physician visits compared to younger patients (from 
4.1 to 8.1 visits/year) [38, 46], one study found those at 
high risk for CV-related comorbidities had higher phy-
sician visit rates compared to those with low risk (20 
vs. 5 visits per year) [53], and one study reported that 
COPD patients diagnosed with GOLD stratum 1–4 had 
a higher number of exacerbations requiring a physician 
visit compared to those with GOLD stratum 0 (15 vs. 9 
visits, respectively) [32]. Goodridge [52] found the high-
est rate of physician visits for COPD patients was within 
12 months of death (28 visits/year) and Rowe [34] found 
that Canadian and US stable COPD patients had similar 
mean annual urgent clinic visit rates. Lastly, two studies 
found that self-management interventions reduced the 
number of unscheduled physician visits [21, 44] and a 
review article found a reduction in the number of annual 




A total of 12 studies were identified describing the 
humanistic burden by measuring the effect of COPD 
on a patient’s health-related quality of life (HRQoL) and 
physical activity (Table  4). Study timeframes were not 
reported in three studies and variation was found in the 
definition of COPD across all studies. With regard to the 
type of HRQoL instruments used, 4 studies [22, 25, 54, 
55] reported outcomes for the 36-item short form health 
survey (SF-36) and 5 studies reported results for The St. 
George Respiratory Questionnaire (SGRQ) [20, 22, 27, 
54, 56]. Other scales that were used to assess HRQoL 
were the chronic respiratory disease (CRD) Index Ques-
tionnaire, the sickness impact profile (SIP) and the 
Chronic Respiratory Questionnaire (CRQ).
Sf‑36
Of the 4 studies reporting SF-36 evidence, one study 
found that COPD patients receiving salmeterol did not 
experience significant improvement in their SF-36 men-
tal or physical health summary scores compared to base-
line [54]. In contrast, a case–control study reported an 
absolute mean difference of 16.9 in the SF-36 physical 
health summary score and 12.8 in the mental component 
score for COPD patients compared to healthy controls. 
The study also indicated a significantly worse (p < 0.001) 
level of functioning for patients with COPD [25].
St George’s Respiratory Questionnaire (SGRQ)
Four of the five studies reporting SGRQ data compared 
an intervention to placebo or usual care in a COPD pop-
ulation [20, 22, 54, 56], while one study reported data for 
COPD patients versus their spouses [27]. Three RCTs 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 19 of 24Dang‑Tan et al. BMC Res Notes  (2015) 8:464 
found pharmaceutical agents (tiotropium, salmeterol, 
tiotropium plus salmeterol and tiotropium plus flutica-
sone/salmeterol) significantly improved patients’ quality 
of life as measured by the SGRQ score [20, 54, 56]. Of the 
remaining two studies, one cross-sectional survey found 
a significant mean difference (5.6, p  =  0.002) for the 
SGRQ impact of disease scores between COPD patients 
and their non-COPD spouse [27] and a prospective, 
observational study reported no significant differences in 
SGRQ scores at baseline between the self-management 
education program and usual care groups [22].
Chronic Respiratory Questionnaire (CRQ)
Three studies used the CRQ to assess the quality of life 
of COPD patients utilizing different pharmaceutical 
interventions (paroxetine, budesonide, prednisone). Of 
the three studies, paroxetine (CRQ emotional function 
domain) and inhaled corticosteroids (budesonide) were 
found to produce significant improvements in patients’ 
quality of life; however, inhaled corticosteroids (even in 
‘high’ doses) did not appear to provide significant HRQoL 
improvement over that achieved with oral prednisone 
[24, 55, 57].
Miscellanous HRQoL instruments
Several studies utilized additional HRQoL instruments 
to assess the quality of life of COPD patients. A study 
by HajGhanbari [25] found that pain severity [measured 
by the McGill Pain Questionnaire (MPQ) and brief pain 
inventory scale (BPI)] showed moderate to strong nega-
tive correlations to the physical component score of the 
SF-36 (−0.45, −0.61, −0.70, respectively; p  <  0.001). In 
addition, a cross-sectional survey study using the SIP 
found significant differences in the mean score between 
patients’ and healthy spouses’ ratings of the SIP physi-
cal score (p  =  0.009), but non-significant differences 
in psychosocial score (p  =  0.497) [27]. Finally, a single 
RCT conducted by Aaron [58] using the chronic respira-
tory disease index HRQoL instrument (CRD) found that 
prednisone use did not result in a significant (p = 0.14) 
overall health benefit (total score) when compared to 
placebo, although prednisone reduced the incidence of 
relapse and improved both lung function and dyspnea.
Physical activity
Three studies reported on physical activity related to 
the burden of COPD. A cross-sectional study using the 
Canadian national health survey data (1994–2007) found 
that approximately 68 % of obese and 60 % of non-obese 
COPD patients were inactive. Additionally, approxi-
mately 72  % of obese and 60  % of non-obese COPD 
patients reported activity restriction [23]. Furthermore, 
a cross-sectional study by Rocker [26] in patients with 
severe, stable COPD found that scores on the pallia-
tive performance scale from semi-structured interviews 
ranged from 50 to 70 % and that all patients had a score 
of 5 on the Medical Research Council dyspnea scale (i.e., 
they were too short of breath to leave their homes or were 
breathless when dressing or undressing). The significance 
of pain in COPD patients was reflected in pain-related 
interference in activities, which may partly account for 
the lower SF-36 physical component scores in HRQoL 
and the lower physical activity scores on the community 




A total of 5 studies contained outcomes of interest and 
were included in this review. Of the 5 studies, 4 stud-
ies reported the patient level direct costs and 2 studies 
reported population level direct costs for COPD patients 
(Tables 5, 6).
Patient level direct costs
Overall, the average total cost per patient was reported 
from both a patient perspective and a society perspec-
tive (accounting for inflation) and ranged between CAN 
$2444.17–CAN $4391.16 (patient perspective) and CAN 
$3910.39–CAN $6693.37 (societal perspective) annually. 
The average cost per acute COPD exacerbation reported 
by Mittmann [3] and Maleki-Yazdi [59] ranged from 
$718–$11,156 and the cost was found to increase with 
the severity of the exacerbation. No studies were found 
to examine the relationship of cost to overall disease 
severity.
Two studies examined differences in costs based on 
patient characteristics. Chapman [1] and Wouters [37] 
both reported female COPD patients incurred more 
costs compared to male patients from both a patient and 
a societal perspective (additional $985/patient from a 
patient perspective, $1513–2138/patient from a societal 
perspective). In addition, these studies also found that 
former smokers incurred more costs than current smok-
ers (additional $1992/patient from a patient perspective, 
$1698–$1744/patient from a societal perspective) and 
that COPD patients with less education incurred more 
costs than those who are more highly educated (addi-
tional $901/patient from a patient perspective, $879–
902/patient from a societal perspective). Lastly, Chapman 
[1] reported that patients with comorbidities were more 
costly than those without comorbidities (additional $136/
patient from a patient perspective, $1440/patient from a 
societal perspective).
Page 20 of 24Dang‑Tan et al. BMC Res Notes  (2015) 8:464 
Population level direct costs
Population level direct costs (in Canadian dollars) were 
examined in two studies (Table 6). Dormuth [60] found 
that residents of British Columbia who were dispensed an 
inhaled anti-cholinergic (IAC) medication (ipratropium 
or tiotropium) cost $26,298,835 annually over 2.5  years 
for IACs (Ministry of Health $13,276,279, out of pocket 
$13,022,556), $310,494,472 for any hospital admis-
sion and $59,456,281 for emergency COPD admissions 
over the 2.5 year period. The second study by Mittmann 
[3] estimated that moderate COPD exacerbations cost 
$182.70–$254.44 million annually while severe exacerba-
tions cost $469.64–$642.26 million annually in Canada.
Discussion
COPD is one of the world’s most common health prob-
lems [2]. This review found evidence that the clinical, 
economic and humanistic burden of COPD is substan-
tial in Canada. COPD patients were found to average 
0–4 annual emergency department visits, 0.3–1.5 annual 
Table 5 Summary of average annual patient level direct costs evidence (CAN$)
ITT intention to treat, NR not reported
References (study period) Categories Patient group Patient perspective 
inflated cost/patient
Societal perspective inflated 
cost/patient
Chapman et al. [1] 
(12 months)
All All $2444.17 $3910.39
Gender Male $1941.09 $2817.88
Female $2926.30 $4956.03
Smoking status Former smokers $3348.67 $4702.55
Current smokers $1357.06 $2958.41
Comorbidities Yes $2506.92 $4568.22
No $2370.68 $3127.96
Education status Less educated $3043.48 $4540.89
More educated $2142.85 $3638.46
Wouters et al. [37] (1 year) All All $2378.59 $6693.37
Gender Male NR $2741.62
Female NR $4254.24
Smoking status Former smokers NR $4575.67
Current smokers NR $2877.75
Education status Less educated NR $4418.73
Well educated NR $3539.53








Maleki‑Yazdi et al. [59] (Oct 
2009 and Jan 2010)
All All $4391.16 NR
Acute exacerbation Clinically evaluable popula‑
tion
$3214.75 NR
Table 6 Summary of average annual population level direct costs evidence (CAN$)
References (study period) Population Resource Inflated 2012 CAN$
Dormuth et al. [60] (Jul 2007–Dec 
2009)




$26,298,835.28 (ministry paid: 
$13,276,279.45, out of pocket: 
$13,022,555.82)
Any hospital admission $310,494,472.10
Emergency COPD admission $59,456,281.50
Mittmann et al. [3] (52 weeks) Mean age of 68.6 years Moderate exacerbation $182.7–$254.44 million
Severe exacerbation $469.64–$642.26 million
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hospital visits, and 0.7–5 annual physician visits which 
are similar to the rates reported worldwide. Variance in 
these rates across studies may reflect population differ-
ences, methodological differences and/or treatment pat-
tern differences between studies. In Canada, the health 
care services are provided by the private sectors but they 
are delivered through publicly funded health care sys-
tems. For instance, basic services such as physician care 
are provided by private doctors but the physician fees are 
paid for by the government. Hospital care is delivered by 
publicly funded hospitals which are mostly independent 
institutions incorporated under provincial Corporations 
Acts. The universal health care system, however, does not 
include coverage of prescription medication; drug benefit 
plans for eligible groups are available under provincial 
and territorial governments.
In terms of ED services, an international survey found 
that around the world, the percentage of COPD patients 
using ED services ranges from 1 % (China) to 25 % (Bra-
zil) [61]. The relatively small number of ED visits found 
for Canadian COPD patients would suggest that the use 
of ED services for COPD patients may fall on the lower 
end worldwide. Hospitalization rates, hospital readmis-
sion rates, and the number of physician visits for Cana-
dian COPD patients were found to be consistent with 
rates found in the US [62–64]. Additionally, trends of 
increasing healthcare resource use as COPD worsens are 
consistent with worldwide data [61, 65].
Primary care has been reported to have the great-
est proportion of worldwide burden in the treatment 
of COPD. Furthermore, increasing severity of COPD 
imposes a greater burden on the use of primary care 
resources [61]. Evidence was found that self-care man-
agement programs may help with reducing the number 
of ED visits, hospitalizations, and physician visits. Addi-
tionally, telephone support services were found to reduce 
the number of physician office visits. Integrated care pro-
grams, however, appear to reduce the mean number of 
hospitalizations but not ED visits.
COPD has a profound impact on patients’ quality of 
life [66]. Evidence found in this review, while not over-
whelming, found that Canadians with COPD have a 
poorer quality of life. Worldwide data suggests that 
up to 45  % of COPD patients experience pain and that 
increases in pain are associated with disease progression 
[67–72]. The significance of pain in COPD patients was 
reflected in greater pain-related interference on activi-
ties of daily living. In the Canadian Hidden Depths sur-
vey, COPD symptoms were found to have a significant 
effect on a range of daily activities (including climbing 
stairs, housework, getting dressed and sleeping) for a 
majority of respondents [73]. Clinicians face challenges 
in treating COPD related pain in that opioids, common 
pharmacotherapy, are not recommended for use in 
COPD patients, presumably due to their effects on the 
reduction of breathing rates which may further exacer-
bate COPD [4]. Additionally, this review found evidence 
that 60–72 % of COPD patients are inactive and/or have 
activity restrictions with obese patients having the high-
est percentages.
Obesity is one of the leading causes of overall morbid-
ity and mortality [74, 75]. Thus it is not surprising that 
health consequences of obesity are seen in the COPD 
population and coupled with progressively worsen-
ing lung function. It is therefore important that more 
research is performed in order to better understand the 
impact of interventions on the quality of life and how to 
maximize patient functioning.
Data from this review found the average total cost 
per COPD patient ranged between CAN $2444 from a 
patient perspective to CAN $6693 from a societal per-
spective. Moreover, data suggests that the costs rise as 
the disease severity increases. The clinical burden review 
found evidence which indicates that healthcare resource 
utilization increases with exacerbation severity [3, 32], 
increasing age [46, 76], and comorbid cardiovascular 
disease [53]. Thus, clinicians should focus on ensuring 
proper diagnosis, optimizing appropriate care, and the 
importance of personalized medicine.
This review, like all reviews, is limited by publication 
bias with respect to the articles that are available. In addi-
tion, the articles in this review were a priori limited to the 
English language and restricted to those published since 
2000 to examine the most recent data as the practice 
of medicine and related burden may change over time. 
Spatial restrictions were also applied, limiting studies to 
Canadian populations. However, in spite of these limita-
tions, this review was systematic in nature and therefore 
by reviewing all available and relevant data, it provides a 
better and comprehensive understanding of the literature 
with respect to clinical, humanistic and economic burden 
of COPD in the Canadian population.
Conclusions
COPD is currently the fourth leading cause of death 
among Canadians. This review found that COPD causes 
a profound impact on healthcare resources and produces 
a significant clinical, humanistic and economic burden in 
Canada. This review found evidence that self-care man-
agement programs, telephone support services, and inte-
grated care programs may help limit the overall burden 
to Canadian patients and society.
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